A message from our CEO about COVID-19 pandemic > IRIDEX



To our valued customers and partners,

As the COVID-19 pandemic continues, our thoughts go out to those who have been impacted. Our priority at IRIDEX is to support our customers, their patients and our employees. We are reacting to the rapidly changing business realities due to the COVID-19 pandemic, with the goals of keeping our ecosystem safe and by adjusting our activities to maintain support of critical production, supply chain and clinical support for our customers.

We want to assure all IRIDEX partners that our sales and clinical teams, as well as our customer service representatives, are available to assist you. We are not currently expecting delays in our supply chain or distribution and are making technical arrangements to support you clinically.

At IRIDEX we are committed to providing our clinical partners the very best training and support. Due to many facilities opting to restrict procedures and operating room access to essential personnel only, we have developed a web page (www.iridex.com/training) to provide you clinical and technical information and resources on our products. This web page will also help with your preparation to perform MicroPulse® Transscleral Laser Therapy with the MicroPulse P3® Device. Our national and international Area Sales Managers and Clinical Application Specialists as well as our distribution partners are available via video conferencing and facetime to answer all surgical and procedural questions and concerns.

We are here to help you. If there is something in particular that you need, please contact your IRIDEX representative, send us an email at info@iridex.com, or visit our contact us page (www.iridex.com/contact). We will remain diligent in monitoring new developments, adjust where necessary, and do our part to manage through this pandemic.

Stay safe and healthy. As we go forward together, please know that we value your questions, ideas and feedback.

David Bruce CEO, IRIDEX

Posted in: News
Actions: E-mail | Permalink |